医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Frontage Laboratories Announces the Acquisition of Philadelphia and Aurora Facilities from Sun Pharmaceuticals by Frontage’s Affiliate, Frontida BioPharm, Inc.

2016年06月07日 AM02:03
このエントリーをはてなブックマークに追加


 

PHILADELPHIA

Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, announced on June 4 that its affiliate company, Frontida BioPharm, Inc. (“Frontida”) has acquired certain assets from a wholly owned US subsidiary of Sun Pharma. The acquisition includes Sun Pharma’s oral solid dosage manufacturing facilities in Philadelphia, PA, and Aurora, IL and 15 related pharmaceutical products (the “Acquired Products”). Terms of the transaction were not disclosed. Frontida has been founded to provide Contract Manufacturing and Co-development services for Frontage’s large base of pharmaceutical industry clients and partners, and will utilize the facilities as its primary base of operations.

In connection with the transaction, Frontida has agreed to continue manufacturing certain products of Sun Pharma at these facilities on a contract basis and offer employment to all production, quality and administrative personnel at the sites. Additionally, Frontida will develop and manufacture the Acquired Products for distribution by commercial partners.

Frontida is offering co-development and commercialization services to pharmaceutical partners in collaboration with Frontage Laboratories’ research facilities in Exton, PA, and its affiliate’s research and development centers in Suzhou and Shanghai, China.

Commenting on the asset purchase, Dr. Song Li, CEO of Frontida BioPharm and Frontage Laboratories, said, “We are pleased to complete this transaction with Sun and partner with them in manufacturing some of their key products. The sites have experienced staff and state-of-the-art facilities and equipment that will serve as a foundation to Frontida’s launch of Contract Development and Manufacturing (“CDMO”) services. Frontida’s CDMO services will complement the high quality development services offered by Frontage Laboratories and provide our long-term clients a trusted partner for product manufacturing and commercial support.”

About Frontage / Frontida:

Frontage, a Tigermed company, a full service early-stage CRO with multiple locations in USA and China has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, it’s full service offerings include DMPK, bioanalysis using 60 LC-MS/MS instruments in support of preclinical and clinical studies, analytical testing, product development, and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health pharmaceutical companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Frontage has successfully enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets.

Frontida Biopharm, Inc., an affiliate of Frontage, is a Contract Development and Manufacturing Organization supporting biopharmaceutical companies in the scale-up and commercial manufacture of immediate and controlled release oral solid dose products. Frontida offers the capability to manufacture Highly Potent Active Ingredient (HPAI) products, Combination Products, as well as DEA schedules II – V products. Its patented Duragran® granulation process eliminates the need for traditional extrusion and compaction manufacturing steps, enhances drug loading, and creates better engineered and lower production-cost controlled release products. Together with Frontage’s CMC development services, Frontida offers Clinical Trial Materials manufacturing, serialized packaging, warehousing, and stability services as well. Frontida is working with Philadelphia and Pennsylvania officials to implement job training programs for skilled workers and support the region’s efforts to retain highly talented pharmaceutical professionals.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160606006212/en/

CONTACT

For more information about Frontida BioPharm, Inc., please contact:
Ron
Connolly
Chief Operations Officer
+1-610-232-0112
ron.connolly@frontidabiopharm.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定
  • オクタファルマ、薬物動態に基づくNuwiq®個別化予防療法(NuPreviq法)に関する新しい臨床データの発表により、血友病A患者への強いコミットメントを浮き彫りに
  • ハーバライフ・ニュートリション、健康的でアクティブな生活を促すリーダーとなれるよう、東南アジアのメンバーを鼓舞